Strategic Network Access As the MedReleaf is a wholly owned subsidiary of Aurora Cannabis, sales opportunities exist within the larger Aurora distribution and customer base, especially in medical cannabis markets and international markets; leverage cross sell for San Rafael 71 products and potential private label partnerships.

European Manufacturing Footprint The Exeter greenhouse investment demonstrates international manufacturing capability and regulatory compliance. This enables B2B sales opportunities with European medical cannabis players and potential toll manufacturing or white label partnerships.

Regulatory Grade Advantage Two state of the art ICH GMP and ISO 9001 certified facilities in Ontario position MedReleaf to pursue pharmaceutical grade contracts with clinics, hospitals, and pharmaceutical distributors, emphasizing quality, traceability, and reliable supply.

Branding and Reputation MedReleaf launched the San Rafael 71 brand, the first adult use recreational line, indicating strong product branding and consumer recognition that can be leveraged for patient education programs, clinical partnerships, and potential co branding with healthcare partners.

Growth Capital Readiness With substantial funding and a narrow revenue band, MedReleaf is positioned to scale operations and modernize manufacturing and supply chain. This opens doors for growth focused partnerships, equipment vendors, and strategic investment opportunities aligned with Aurora’s ecosystem.